Clinical trial · Observational
Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients With Pancreas Cancer
iPC3 - Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients With Pancreas Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): study was closed by PI due to no accrual
Summary
Brief summary (as posted)
The main purpose of this study is to evaluate the acceptance by patients with metastatic pancreas cancer of integrating palliative care with usual cancer treatment. Palliative care intervention will involve use of pancreas cancer-specific decision aides (iPC3)about prognosis, treatment choices, and advance care planning for patients facing a treatment decision as well as symptom assessments. We hypothesize that palliative care consultations with iPC3 will be accepted, symptoms can be diminished, information can be received in a way that improves choices, and that the quality of care can be improved.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Palliative care with decision aids | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- palliative care with iPC3
- description
- Palliative care with decision aids will be administered at each palliative care visit.
- interventionNames
- Other: Palliative care with decision aids
Primary outcomes (1)
- measure
- Feasibility of the patients with metastatic pancreas cancer to meet with the palliative care team and to complete symptom assessments.
- timeFrame
- participants will be followed monthly until referred to hospice or until death, an expected average of 1 year
Secondary outcomes (3)
- measure
- Changes in symptoms listed in the Memorial Symptom Assessment Scale (condensed version)
- timeFrame
- participants will be followed monthly until referred to hospice or until death, an expected average of 1 year
- description
- The condensed Memorial Symptom Assessment Scale evaluates 14 symptoms: lack of energy, lack of appetite, pain, dry mouth, weight loss, feeling drowsy, shortness of breath, constipation, difficulty sleeping, difficulty concentrating, nausea, worrying, feeling sad, and feeling nervous.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * All patients with metastatic pancreas cancer will be eligible, ages 18 and above. * There is no limit to the amount of prior therapy for metastatic disease. * Ability to understand and the willingness to sign a written informed consent document and to answer a questionnaire. * English speakers. Exclusion Criteria: * Patients who have tumors other than metastatic pancreas cancer. * Patients who actively decline participation or who are judged to be in distress before the interview. * Patients who are pregnant.
References
Publications (2)
- BACKGROUNDTemel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010 Aug 19;363(8):733-42. doi: 10.1056/NEJMoa1000678. PMID 20818875
- BACKGROUNDSmith TJ, Temin S, Alesi ER, Abernethy AP, Balboni TA, Basch EM, Ferrell BR, Loscalzo M, Meier DE, Paice JA, Peppercorn JM, Somerfield M, Stovall E, Von Roenn JH. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol. 2012 Mar 10;30(8):880-7. doi: 10.1200/JCO.2011.38.5161. Epub 2012 Feb 6. PMID 22312101